Peritoneal sclerosis - Aetiology, diagnosis, treatment and prevention

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 2, 2006, Pages

  Cnossen, Trijntje T ^a   Konings, Constantijn J A M ^a   Kooman, Jeroen P ^b   Lindholm, Bengt ^c  

^a CATHARINA HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CA 125 ANTIGEN; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; CORTICOSTEROID; GELATINASE A; GELATINASE B; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PENTOXIFYLLINE; PERITONEAL DIALYSIS FLUID; RAPAMYCIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ABDOMINAL RADIOGRAPHY; ABDOMINAL SURGERY; ARTICLE; BIOCOMPATIBILITY; CELL TRANSFORMATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG MECHANISM; EARLY DIAGNOSIS; FATALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MESOTHELIUM CELL; MORTALITY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL SCLEROSIS; PERITONITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS; RISK FACTOR; STAPHYLOCOCCUS AUREUS; TOTAL PARENTERAL NUTRITION;

HUMANS; PERITONEAL DIALYSIS; PERITONEUM; RISK FACTORS; SCLEROSIS;

EID: 33745771305     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl189     Document Type: Article

References (40)

1. Garosi G, di Paolo N. Perit Sclerosis, an overview. Adv Perit Dial 1999; 15: 185-192
2. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17 [Suppl 3]: 12-5
3. Garosi G, di Paolo N. Morphological aspects of peritoneal sclerosis. J Nephrol 2001; 14 [Suppl 4]: S30-S38
4. Cancarini GS, Sandrini M, Vizzardi V, Bertoli S, Buzzi L, Maiorca R. Clinical aspects of peritoneal sclerosis. J Nephrol 2001; 14 [Suppl 4]: S39-S47
5. Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159
6. Kawanishi H, Kawaguchi Y, Fukui H et al. Encapsulating peritoneal sclerosis in Japan: A prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44: 729
7. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136-143
8. Lee HY, Kim BS, Choi HY et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2003; 8 [Suppl]: S33-S39
9. Lo WK, Chan KT, Leung AC, Pang SW, Tse CY. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol. Adv Perit Dial 1990; 6: 79-84
10. Kawaguchi Y, Tranaeus A. A historical review of encapsulating peritoneal sclerosis. Perit Dial Int (in press).
11. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3: 66-69
12. Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159
13. Kjellstrand P, Martinson E, Wieslander A. Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature. Perit Dial Int 1995; 15: 26-32
14. Schalkwijk CG, Posthuma N, ten Brink HJ. Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of advanced glycation endproducts, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999; 19: 325-333
15. ε-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280: 1408-1414
16. Nakamura S, Miyazaki S, Sasaki S. Localization of imidazolone in the peritoneum of CAPD patients: A factor for a loss of ultrafiltration. Am J Kidney Dis 2001; 38: S107-S110
17. Honda K, Nitta K, Horita S. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549
18. Nakamura S, Miyazaki S, Sasaki S. Localization of imidazolone in the peritoneum of CAPD patients: A factor for a loss of ultrafiltration. Am J Kidney Dis 2001; 38: S107-S110
19. Miyata T, Horie K, Ueda Y. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435
20. Honda K, Nitta K, Horita S. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549
21. Nakamura S, Tachikawa T, Tobita K et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003; 41 [3 Suppl 1]: S61-S67
22. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541
23. Numata M, Nakayama M, Hosoya T et al. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin Nephrol 2004; 62: 455-460
24. Kawanishi H. Encapsulating peritoneal sclerosis. Nephrology 2005; 10: 249-255
25. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9: 187-189
26. Campbell S, Clarke P, Hawley C et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis 1994; 24: 819-825
27. Krestin GP, Kacl G, Hoffmann R, Keusch G, Burger HR. Rofo. The imaging diagnosis of sclerosing peritonitis following continuous ambulatory peritoneal dialysis. 1992; 157: 506-511
28. Williams JD, Craig KJ, Topley N et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
29. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888-893
30. Mateijsen MA, van der Wal AC, Hendriks PM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525
31. Moriishi M, Kawanishi H, Kawai T et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18: 149-153
32. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30: 275-278
33. Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: Tamoxifen as a new therapeutic agent? J Nephrol 1999; 12: 395-397
34. Del Peso G, Bajo MA, Gil F et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19: 32-35
35. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004; 19: 2423-2424
36. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 2002; 17: 2278-2280
37. Hawley CM, Wall DR, Johnson DW et al. Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1995; 26: 658-661
38. Kawanishi H, Harada Y, Sakikubo E, Moriishi M, Nagai T, Tsuchiya S. Surgical treatment for sclerosing encapsulating peritonitis. Adv Perit Dial 2000; 16: 252-256
39. Celicout B, Levard H, Hay J, Msika S, Fingerhut A, Pelissier E. Sclerosing encapsulating peritonitis: Early and late results of surgical management in 32 cases. French Associations for Surgical Research. Dig Surg 1998; 15: 697-702
40. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ. Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: Implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003; 18: 670-676